AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29937161 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 221
Study 27693866 — intervention group
Group type: EXPERIMENTAL
Intervention: Current comorbid psychiatric disorders (mood disorders present in 33.6%, anxiety disorders in 29.6%)
Number of subjects: 302
Study 27693866 — intervention group
Group type: EXPERIMENTAL
Intervention: Other stimulant use disorder
Number of subjects: 302
Study 27693866 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more comorbid psychiatric disorders
Number of subjects: 302
Study 27693866 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more comorbid disorders
Number of subjects: 302
Study 24398649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (60,000 IU/week for 8 weeks followed by 60,000 IU/fortnight)
Number of subjects: 131
Study 24398649 — intervention group
Group type: COMPARATOR
Intervention: Calcium (elemental calcium 500 mg twice/day)
Number of subjects: 131
Study 24398649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual supplementation (Cholecalciferol and Calcium)
Number of subjects: 131
Study 24398649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 22568596 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 54
Study 22568596 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan
Number of subjects: 54
Study 19710188 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐(‐)[2‐13C]equol
Number of subjects: 12
Study 19710188 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐(+)[2‐13C]equol
Number of subjects: 12
Study 19710188 — intervention group
Group type: COMPARATOR
Intervention: Racemic (+/‐)[2‐13C]equol
Number of subjects: 12
Study 17313263 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine, amino acids, and protein drink (TEST)
Number of subjects: 51
Study 17313263 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo (PLAC)
Number of subjects: 51
Study 17313263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TEST and PLAC
Number of subjects: 51
Study 15172106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Magnetic Field (MF) exposure for 30 minutes
Number of subjects: 70
Study 15172106 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure for 30 minutes
Number of subjects: 70
Study 15172106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Magnetic Field (MF) exposure
Number of subjects: 70
Study 11270805 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid Solutab tablet (500/125)
Number of subjects: 48
Study 11270805 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid Solutab tablet (500/125) after excluding outliers
Number of subjects: 48
Study 11270805 — intervention group
Group type: COMPARATOR
Intervention: Augmentan film‐coated tablet (reference)
Number of subjects: 48
Study 11270805 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid Solutab tablet (intact or dispersed)
Number of subjects: 48
Study 9601680 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal activity in the visual cortex observed approximately 100-200 ms from stimulus onset.
Number of subjects: 0
Study 9601680 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal activity in the inferior parietal lobe observed after 200 ms.
Number of subjects: 0
Study 9601680 — intervention group
Group type: EXPERIMENTAL
Intervention: Premotor activity started later than the inferior parietal lobe activity.
Number of subjects: 0
Study 9601680 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity in primary motor and/or motosensory areas observed in some subjects.
Number of subjects: 0
Study 7977274 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of dehydroepiandrosterone sulfate (DHEAS)
Number of subjects: 338
Study 7977274 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 338
Study 2693503 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O-600 (600 mg orally R every 8 hours for 48 hours followed by 200 mg every 8 hours for 72 hours, total dose 5.4 g)
Number of subjects: 16
Study 2693503 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O-800 (800 mg orally R every 8 hours for 24 hours followed by 400 mg every 12 hours for 96 hours, total dose 4.1 g)
Number of subjects: 16
Study 2693503 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A-40 (aerosolized R 40 mg/ml for 6 hours every 12 hours for 96 hours, average delivered dose 6.2 g)
Number of subjects: 16
Study 2693503 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A-60 (aerosolized R 60 mg/ml for 2 hours every 8 hours for 96 hours, average delivered dose 4.6 g)
Number of subjects: 16
Study 802071 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine alone
Number of subjects: 30
Study 802071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (Viskén) combined with hydralazine
Number of subjects: 30
Study 31594904 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard condition of test administration (assumed to activate negative ageing stereotypes)
Number of subjects: 260
Study 31594904 — intervention group
Group type: COMPARATOR
Intervention: Reduced-threat instruction condition (designed to alleviate anxiety from stereotypes)
Number of subjects: 260
Study 27825592 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 18
Study 27825592 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat insoles
Number of subjects: 18
Study 26529159 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based therapy
Number of subjects: 300
Study 26529159 — intervention group
Group type: COMPARATOR
Intervention: ritonavir-boosted lopinavir-based therapy
Number of subjects: 300
Study 23622123 — intervention group
Group type: EXPERIMENTAL
Intervention: Online multi-component psychoeducational intervention
Number of subjects: 0
Study 23622123 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention semi-structured interview with 20% of participants
Number of subjects: 0
Study 21809439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark roast coffee (NMP: 785 μmol/L, CGA: 523 μmol/L)
Number of subjects: 30
Study 21809439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark roast coffee
Number of subjects: 30
Study 21809439 — intervention group
Group type: COMPARATOR
Intervention: Light roast coffee (CGA: 4538 μmol/L, NMP: 56 μmol/L)
Number of subjects: 30
Study 18486785 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation to surgically created sockets
Number of subjects: 62
Study 18486785 — intervention group
Group type: COMPARATOR
Intervention: Transplantation to fresh extraction sites (Control)
Number of subjects: 62
Study 16813473 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (50 minutes, 3 times a week for 12 weeks)
Number of subjects: 30
Study 16813473 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program
Number of subjects: 30
Study 16813473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 30
Study 14593691 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate multi-family psychoeducation groups (MFPG) plus treatment as usual
Number of subjects: 35
Study 14593691 — intervention group
Group type: COMPARATOR
Intervention: 6-month wait-list condition plus treatment as usual
Number of subjects: 35
Study 11069436 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug epidemiology studies
Number of subjects: 0
Study 11069436 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study 11069436 — intervention group
Group type: EXPERIMENTAL
Intervention: New-users of the drug
Number of subjects: 0
Study 11069436 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug epidemiology
Number of subjects: 0
Study 8755685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/d (increased to 40 mg/d if inadequate response)
Number of subjects: 24
Study 8755685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg + indomethacin 75 mg/d
Number of subjects: 24
Study 8755685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1389702 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice a day
Number of subjects: 170
Study 1389702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 3880480 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudragit E 100-coated microcapsules
Number of subjects: 20
Study 3880480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylcellulose-coated microcapsules
Number of subjects: 20
Study 3880480 — intervention group
Group type: COMPARATOR
Intervention: Reference tablet
Number of subjects: 20
Study 3880480 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated intestinal fluid with adjusted ionic strength
Number of subjects: 20
Study 3880480 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudragit E 100 polymer
Number of subjects: 20
Study 28152246 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max CAD (DM group)
Number of subjects: 30
Study 28152246 — intervention group
Group type: COMPARATOR
Intervention: Lava Plus (LM group)
Number of subjects: 30
Study 28152246 — intervention group
Group type: COMPARATOR
Intervention: Metal‐ceramic (MC group)
Number of subjects: 30
Study 29678772 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose minocycline (200 mg per day)
Number of subjects: 75
Study 29678772 — intervention group
Group type: COMPARATOR
Intervention: Minocycline (both doses)
Number of subjects: 75
Study 27126487 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PMTCT care package
Number of subjects: 369
Study 27126487 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 369
Study 25159234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control targeting glycated hemoglobin level of <6.0%
Number of subjects: 10082
Study 25159234 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control targeting glycated hemoglobin level of 7.0% to 7.9%
Number of subjects: 10082
Study 25159234 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM and new-onset AF
Number of subjects: 10082
Study 22479327 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 40
Study 22479327 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC
Number of subjects: 40
Study 20226994 — intervention group
Group type: EXPERIMENTAL
Intervention: EGG breakfast
Number of subjects: 21
Study 20226994 — intervention group
Group type: COMPARATOR
Intervention: BAGEL breakfast
Number of subjects: 21
Study 17899016 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 12
Study 17899016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15863797 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean modal dose=3.3 mg)
Number of subjects: 555
Study 15863797 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean modal dose=2.9 mg)
Number of subjects: 555
Study 15863797 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 555
Study 15863797 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 555
Study 12202661 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 mg/m²/d) and LV (75 or 90 mg/d) for 28 days every 35 days
Number of subjects: 816
Study 12202661 — intervention group
Group type: COMPARATOR
Intervention: IV bolus 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) for 5 days every 28 days
Number of subjects: 816
Study 12202661 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 816
Study 12202661 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 816
Study 10599373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing alone
Number of subjects: 39
Study 10599373 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone propionate cream alone
Number of subjects: 39
Study 10599373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies combined (hydrocolloid dressing and Betamethasone propionate cream)
Number of subjects: 39
Study 8942719 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 16
Study 8942719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 16
Study 8942719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 16
Study 2018160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Number of subjects: 94
Study 2018160 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 94
Study 2018160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 2018160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy with buspirone
Number of subjects: 94
Study 2018160 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavior therapy with placebo
Number of subjects: 94
Study 7043002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 38
Study 31603392 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 2732
Study 31603392 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Physical Activity
Number of subjects: 2732
Study 31603392 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 2732
Study 31603392 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA)
Number of subjects: 2732
Study 31603392 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Inactivity
Number of subjects: 2732
Study 31603392 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic Level
Number of subjects: 2732
Study 31797855 — intervention group
Group type: EXPERIMENTAL
Intervention: Quirynen's protocol of one‐stage full‐mouth disinfection
Number of subjects: 40
Study 31797855 — intervention group
Group type: COMPARATOR
Intervention: Bollen's protocol of one‐stage full‐mouth disinfection
Number of subjects: 40
Study 28338180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg in 20 ml infused for 10 min)
Number of subjects: 93
Study 28338180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine (0.1 mg/kg in 20 ml infused for 10 min)
Number of subjects: 93
Study 28338180 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 ml NS infused intravenously 10 min before anesthetic induction)
Number of subjects: 93
Study 28338180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 25652752 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrode stimulation for 3 months followed by sham stimulation for 3 months (ON-OFF arm)
Number of subjects: 5
Study 25652752 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 3 months followed by active stimulation for 3 months (OFF-ON arm)
Number of subjects: 5
Study 24167370 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose series of nonadjuvated monovalent influenza A H1N1 2009 vaccine
Number of subjects: 45
Study 21161699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 24
Study 21161699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19527979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stents (SES)
Number of subjects: 712
Study 19527979 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 712
Study 17069486 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser needle irradiation on the right forearm at acupuncture point Pe6
Number of subjects: 33
Study 17069486 — intervention group
Group type: COMPARATOR
Intervention: No laser irradiation (Control group)
Number of subjects: 33
Study 15346229 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours of sleep deprivation with intermittent physical exercise (cycling at 50% VO2peak for 20 min every 2 hours)
Number of subjects: 6
Study 15346229 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activities (control group)
Number of subjects: 6
Study 12577420 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza (SM) and Astragalus membranaceus (AM)
Number of subjects: 84
Study 12577420 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 84
Study 9264433 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 to 80 mg/day)
Number of subjects: 0
Study 8221271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (14.4% NaCl)
Number of subjects: 19
Study 8221271 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 19
Study 3303978 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) combined with exercise
Number of subjects: 22
Study 3303978 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (Control)
Number of subjects: 22
Study 3303978 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive athletes
Number of subjects: 22
Study 3303978 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational athletes
Number of subjects: 22
Study 29663363 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM19A4/mir124-2 methylation test
Number of subjects: 1040
Study 29663363 — intervention group
Group type: COMPARATOR
Intervention: Cytology test (threshold borderline dyskaryosis or ASCUS)
Number of subjects: 1040
Study 27959701 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose crizanlizumab (5.0 mg/kg)
Number of subjects: 198
Study 27959701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 26041682 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRA‐C intervention delivered via the Internet or tablet at the clinic
Number of subjects: 0
Study 26041682 — intervention group
Group type: COMPARATOR
Intervention: ESRA‐C assessment only (control)
Number of subjects: 0
Study 23915107 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter (n=17,068)
Number of subjects: 31452
Study 23915107 — intervention group
Group type: COMPARATOR
Intervention: No invitation letter (Control group, n=14,384)
Number of subjects: 31452
Study 23915107 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter effectiveness
Number of subjects: 31452
Study 21430075 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of lycopene as a tomato oleoresin for 21 days
Number of subjects: 105
Study 21430075 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 105
Study 18662629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 32
Study 18662629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16282635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject advocate procedures
Number of subjects: 73
Study 14755152 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal preparation STW 5‐II
Number of subjects: 120
Study 14755152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11839319 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 0
Study 11839319 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia
Number of subjects: 0
Study 9728734 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 1507
Study 9728734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 1507
Study 9728734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg flunitrazepam
Number of subjects: 1507
Study 9728734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1507
Study 7994508 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg daily to 1.2 mg daily over 14 days)
Number of subjects: 86
Study 7994508 — intervention group
Group type: COMPARATOR
Intervention: Dummy medication (placebo)
Number of subjects: 86
Study 3133964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 16
Study 3133964 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol
Number of subjects: 16
Study 3133964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate plus reproterol
Number of subjects: 16
Study 3133964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30586113 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Duration HIIT (SDHIIT, n = 10)
Number of subjects: 30
Study 30586113 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Duration HIIT (LDHIIT, n = 10)
Number of subjects: 30
Study 30586113 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 30
Study 28266963 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-45070 ointment
Number of subjects: 70
Study 28266963 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 70
Study 28266963 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-45070 ointment in patients with R1150W polymorphism
Number of subjects: 70
Study 28266963 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-45070 ointment in wild-type carriers
Number of subjects: 70
Study 26556051 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study 26556051 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study 23139215 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic conditioned media (PCM)
Number of subjects: 0
Study 23139215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis conditioned media
Number of subjects: 0
Study 23139215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus conditioned media
Number of subjects: 0
Study 23139215 — intervention group
Group type: COMPARATOR
Intervention: Tollip siRNA-mediated knockdown
Number of subjects: 0
Study 22018587 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard non-hydrolysed cows' milk-based formula with a mixture of specific oligosaccharides (prebiotics group)
Number of subjects: 830
Study 22018587 — intervention group
Group type: COMPARATOR
Intervention: Similar formula without oligosaccharides (control group)
Number of subjects: 830